Sonia Reyes Neurology & CNS Disorders | Apr 23, 2026 Gefurulimab, a once-weekly self-administered subcutaneous nanobody for gMG, met phase 3 PREVAIL endpoints at Week 26, potentially shifting care away from IV infusion centers.
George Padron Precision Medicine, Specialty Medicine, Neurology & CNS Disorders | Apr 23, 2026 Real-world INFUSE study data at AAN 2026 show eptinezumab improves migraine-related cognitive symptoms in over 50% of patients with prior anti-CGRP failure at 6 months.
Sonia Reyes Neurology & CNS Disorders, Obesity & Metabolic Health | Apr 23, 2026 A living systematic review at AAN 2026 shows GLP-1 receptor agonists cut real-world dementia risk but failed to slow Alzheimer's progression in phase 3 trials.
🔎︎
